| Leslie Larsen Cuiper, MD | |
|
8101 Hinson Farm Road, Suite 306, Alexandria, VA 22306 | |
| (703) 780-3536 | |
| (703) 780-2918 |
| Full Name | Leslie Larsen Cuiper |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine - Pulmonary Disease |
| Location | 8101 Hinson Farm Road, Alexandria, Virginia |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386735306 | NPI | - | NPPES |
| 010034809 | Medicaid | VA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | 0101234445 (Virginia) | Primary |
| Entity Name | Inova Health Care Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952320061 PECOS PAC ID: 2466351093 Enrollment ID: O20040102000644 |
News Archive
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced that on Friday, October 29, 2010 it submitted a complete response to the "Complete Response" letter issued by the U.S. Food and Drug Administration (FDA), regarding its supplemental New Drug Application (sNDA) for FUSILEV (levoleucovorin) for Injection for treatment of patients with advanced metastatic colorectal cancer.
A new program project grant from the National Cancer Institute will fund research by the Translational Center of Excellence for Lung Cancer Immunology at the Abramson Cancer Center of the University of Pennsylvania to improve the effectiveness of chimeric antigen receptor T cell therapy at fighting solid tumors.
The Substance Abuse and Mental Health Services Administration (SAMHSA) announced today it is awarding up to 29 new grants, totaling up to $25 million over three years, to expand use of health information technology to increase access to behavioral health services.
Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today announced that the Phase 3 HannaH trial, conducted by Roche, showed that women with HER2-positive early breast cancer who received a new, investigational subcutaneous (SC) injection of Herceptin (trastuzumab), experienced comparable results to Herceptin given as an intravenous infusion.
Akeso Medical Imaging BV, announces today the start of a clinical study with their novel imaging device for assessment of joint inflammation in patient with rheumatoid arthritis (RA). In this proof of concept study, Akeso's imaging device will be compared to other methods to assess disease status, such as the DAS-28 score, Ultrasound and in some cases MRI. The study will be performed at the University Medical Center Utrecht (UMC Utrecht) in cooperation with Regional Rheumatology Centre Eindhoven (RRC). Seventy subjects will be included; sixty RA patients with varying degrees of inflammation of the joints of hands and wrists at the time of examination and a control group of ten subjects.
› Verified 2 days ago
| Entity Name | Asthma And Pulmonary Specialists Of No Va Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053466268 PECOS PAC ID: 7214830181 Enrollment ID: O20040128001012 |
News Archive
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced that on Friday, October 29, 2010 it submitted a complete response to the "Complete Response" letter issued by the U.S. Food and Drug Administration (FDA), regarding its supplemental New Drug Application (sNDA) for FUSILEV (levoleucovorin) for Injection for treatment of patients with advanced metastatic colorectal cancer.
A new program project grant from the National Cancer Institute will fund research by the Translational Center of Excellence for Lung Cancer Immunology at the Abramson Cancer Center of the University of Pennsylvania to improve the effectiveness of chimeric antigen receptor T cell therapy at fighting solid tumors.
The Substance Abuse and Mental Health Services Administration (SAMHSA) announced today it is awarding up to 29 new grants, totaling up to $25 million over three years, to expand use of health information technology to increase access to behavioral health services.
Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today announced that the Phase 3 HannaH trial, conducted by Roche, showed that women with HER2-positive early breast cancer who received a new, investigational subcutaneous (SC) injection of Herceptin (trastuzumab), experienced comparable results to Herceptin given as an intravenous infusion.
Akeso Medical Imaging BV, announces today the start of a clinical study with their novel imaging device for assessment of joint inflammation in patient with rheumatoid arthritis (RA). In this proof of concept study, Akeso's imaging device will be compared to other methods to assess disease status, such as the DAS-28 score, Ultrasound and in some cases MRI. The study will be performed at the University Medical Center Utrecht (UMC Utrecht) in cooperation with Regional Rheumatology Centre Eindhoven (RRC). Seventy subjects will be included; sixty RA patients with varying degrees of inflammation of the joints of hands and wrists at the time of examination and a control group of ten subjects.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Leslie Larsen Cuiper, MD 3601 Norris Place, Alexandria, VA 22305 Ph: (703) 549-1999 | Leslie Larsen Cuiper, MD 8101 Hinson Farm Road, Suite 306, Alexandria, VA 22306 Ph: (703) 780-3536 |
News Archive
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced that on Friday, October 29, 2010 it submitted a complete response to the "Complete Response" letter issued by the U.S. Food and Drug Administration (FDA), regarding its supplemental New Drug Application (sNDA) for FUSILEV (levoleucovorin) for Injection for treatment of patients with advanced metastatic colorectal cancer.
A new program project grant from the National Cancer Institute will fund research by the Translational Center of Excellence for Lung Cancer Immunology at the Abramson Cancer Center of the University of Pennsylvania to improve the effectiveness of chimeric antigen receptor T cell therapy at fighting solid tumors.
The Substance Abuse and Mental Health Services Administration (SAMHSA) announced today it is awarding up to 29 new grants, totaling up to $25 million over three years, to expand use of health information technology to increase access to behavioral health services.
Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today announced that the Phase 3 HannaH trial, conducted by Roche, showed that women with HER2-positive early breast cancer who received a new, investigational subcutaneous (SC) injection of Herceptin (trastuzumab), experienced comparable results to Herceptin given as an intravenous infusion.
Akeso Medical Imaging BV, announces today the start of a clinical study with their novel imaging device for assessment of joint inflammation in patient with rheumatoid arthritis (RA). In this proof of concept study, Akeso's imaging device will be compared to other methods to assess disease status, such as the DAS-28 score, Ultrasound and in some cases MRI. The study will be performed at the University Medical Center Utrecht (UMC Utrecht) in cooperation with Regional Rheumatology Centre Eindhoven (RRC). Seventy subjects will be included; sixty RA patients with varying degrees of inflammation of the joints of hands and wrists at the time of examination and a control group of ten subjects.
› Verified 2 days ago
George Peter Silis, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 5115 Franconia Road, Sutie G, Alexandria, VA 22310 Phone: 703-922-4222 Fax: 703-922-4253 | |
Dr. Madhusudanan Srambickal Ramaswamy, M.D., M.S. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 4320 Seminary Rd, Alexandria, VA 22304 Phone: 703-504-3000 Fax: 571-285-0027 | |
Nabeela Tabassum, M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 4810 Beauregard St, Ste 303, Alexandria, VA 22312 Phone: 703-750-0108 Fax: 703-750-0230 | |
Dr. Chinedu Madu, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 4825 Mark Center Dr Ste 150, Alexandria, VA 22311 Phone: 703-751-8111 Fax: 703-751-1105 | |
Kim-dung T Nguyen, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 5130 Duke St, 8, Alexandria, VA 22304 Phone: 703-823-2849 Fax: 703-823-2847 | |
Dr. Muhammed F. Khokhar, Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 4660 Kenmore Ave Ste 810, Alexandria, VA 22304 Phone: 703-823-0333 Fax: 703-823-8611 | |
Tariq Rehman, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 4141a Duke St, Alexandria, VA 22304 Phone: 703-461-3556 Fax: 703-461-8075 |